White Paper

Conducting Research With CAR T Cells 

Regulatory and Practical Considerations 

Having proven successful in trials for blood cancers considered resistant or refractory to traditional treatment, CAR T is now expanding into rare diseases and nonmalignant conditions.

This white paper is an indispensable guide for research professionals looking to conduct CAR T cell studies for the first time, as well as for those seeking to expand their existing portfolio.

Some of the insights you’ll gain:

  • What FDA guidance means for CAR T trials
  • Facilities and infrastructure needs for participating sites
  • Safety considerations for patients, staff, and others

Download the white paper.





Who should watch?

text goes here

CEU Credits

text goes here

Certificate of Attendance

text goes here

DATE
Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Access Now